Molecular Periphery Design Allows Control of the New Nitrofurans Antimicrobial Selectivity
Lyubov Vinogradova,
Alexey Lukin,
Kristina Komarova,
Maxim Zhuravlev,
Artem Fadeev,
Mikhail Chudinov,
Elizaveta Rogacheva,
Lyudmila Kraeva,
Maxim Gureev,
Yuri Porozov,
Marine Dogonadze,
Tatiana Vinogradova
Affiliations
Lyubov Vinogradova
Lomonosov Institute of Fine Chemical Technologies, MIREA—Russian Technological University, 119454 Moscow, Russia
Alexey Lukin
Lomonosov Institute of Fine Chemical Technologies, MIREA—Russian Technological University, 119454 Moscow, Russia
Kristina Komarova
Lomonosov Institute of Fine Chemical Technologies, MIREA—Russian Technological University, 119454 Moscow, Russia
Maxim Zhuravlev
Lomonosov Institute of Fine Chemical Technologies, MIREA—Russian Technological University, 119454 Moscow, Russia
Artem Fadeev
Lomonosov Institute of Fine Chemical Technologies, MIREA—Russian Technological University, 119454 Moscow, Russia
Mikhail Chudinov
Lomonosov Institute of Fine Chemical Technologies, MIREA—Russian Technological University, 119454 Moscow, Russia
Elizaveta Rogacheva
Pasteur Institute of Epidemiology and Microbiology, 197101 Saint Petersburg, Russia
Lyudmila Kraeva
Pasteur Institute of Epidemiology and Microbiology, 197101 Saint Petersburg, Russia
Maxim Gureev
Institute of Cytology, Russian Academy of Sciences, Tikhoretsky Ave. 4, 194064 Saint Petersburg, Russia
Yuri Porozov
Laboratory of Angiopathology, The Institute of General Pathology and Pathophysiology, 8 Baltiyskaya Street, 125315 Moscow, Russia
Marine Dogonadze
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation, 191036 Saint Petersburg, Russia
Tatiana Vinogradova
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation, 191036 Saint Petersburg, Russia
A series of 13 new 3-substituted 5-(5-nitro-2-furyl)-1,2,4-oxadiazoles was synthesized from different aminonitriles. All compounds were screened in the disc diffusion test at a 100 μg/mL concentration to determine the bacterial growth inhibition zone presence and diameter, and then the minimum inhibitory concentrations (MICs) were determined for the most active compounds by serial dilution. The compounds showed antibacterial activity against ESKAPE bacteria, predominantly suppressing the growth of 5 species out of the panel. Some compounds had similar or lower MICs against ESKAPE pathogens compared to ciprofloxacin, nitrofurantoin, and furazidin. In particular, 3-azetidin-3-yl-5-(5-nitro-2-furyl)-1,2,4-oxadiazole (2h) inhibited S. aureus at a concentration lower than all comparators. Compound 2e (5-(5-nitro-2-furyl)-3-[4-(pyrrolidin-3-yloxy)phenyl]-1,2,4-oxadiazole) was active against Gram-positive ESKAPE pathogens as well as M. tuberculosis. Differences in the molecular periphery led to high selectivity for the compounds. The induced-fit docking (IFD) modeling technique was applied to in silico research. Molecular docking results indicated the targeting of compounds against various nitrofuran-associated biological targets.